Selective α7 nicotinic acetylcholine receptor ligands for the treatment of neuropsychiatric diseases

Drugs of the Future

Volumn 32, Issue 2, 2007, Pages 161-170

  Broad, Lisa M ^a   Sher, Emanuele ^a   Astles, Peter C ^a   Zwart, Ruud ^a   O'Neill, Michael J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(2 AMINO 5 KETO)THIAZOLE DERIVATIVE; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 ETHYNYL 5 (1 METHYL 2 PYRROLIDINYL)PYRIDINE FUMARATE; 3 PYRAZINOXYQUINUCLIDINE DERIVATIVE; 5 HYDROXYINDOLE; ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGAND; ARR 17779; ARR 234655; BENZAMIDE DERIVATIVE; BUNGAROTOXIN RECEPTOR; DIHYDRO BETA ERYTHROIDINE; DRUG METABOLITE; GALANTAMINE; IVERMECTIN; MEM 3454; MEM 63908; NICOTINE; NICOTINIC AGENT; OXAZOLIDINONE DERIVATIVE; PHA 543613; PHA 543913; PNU 120596; PNU 282987; PSAB OFP; QUINUCLIDINE BENZAMIDE DERIVATIVE; QUINUCLIDINE DERIVATIVE; SPIRO [1AZABICYCLO[2.2.2] OCTANE 3,5 OXAZOLIDIN] 2 ONE DERIVATIVE; SSR 180711; TC 5619; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; BRAIN ELECTROPHYSIOLOGY; COGNITION; DEGENERATIVE DISEASE; DRUG ANTAGONISM; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MENTAL DISEASE; NEUROPSYCHIATRY; NONHUMAN; REVIEW; SCHIZOPHRENIA; UNSPECIFIED SIDE EFFECT;

EID: 34247486496     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.02.1064020     Document Type: Review

References (80)

1. Fabian-Fine, R., Skehel, P., Errington, M.L. et al. Ultrastructural distribution of the alpha7 nicotinic acetylcholine receptor subunit in rat hippocampus. J Neurosci 2001, 21(20): 7993-8003.
2. Marchi, M., Risso, F., Viola, C. et al. Direct evidence that release-stimulating alpha7 nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals. J Neurochem 2002, 80: 1071-8.
3. Levin, E.D. Nicotinic receptor subtypes and cognitive function. J Neurobiol 2002, 53(4): 633-40.
4. Levin, E.D., Bradley, A., Addy, N. et al. Hippocampal alpha 7 and alpha 4 beta 2 nicotinic receptors and working memory. Neuroscience 2002, 109(4): 757-65.
5. De Luca, V., Wong, A.H., Muller, D.J. et al. Evidence of association between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients. Neuropsychopharmacology 2004, 29(8): 1522-6.
6. Leonard, S., Breese, C., Adams, C. et al. Smoking and schizophrenia: Abnormal nicotinic receptor expression. Eur J Pharmacol 2000, 393(1-3): 237-42.
7. Perry, E., Martin-Ruiz, C., Lee, M. et al. Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur J Pharmacol 2000, 393(1-3): 215-22.
8. Hogg, R.C., Bertrand, D. Partial agonists as therapeutic agents at neuronal nicotinic acetylcholine receptors. Biochem Pharmacol 2006, Epub ahead of print.
9. Mullen, G., Napier, J, Balestra, M. et al. (-)-Spiro[1-azabicyclo[2.2. 2]octane-3,5′-oxazolidin-2′-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the alpha 7 nicotinic acetylcholine receptor. J Med Chem 2000, 43(22): 4045-50.
10. Phillips, E., Mack, R., Macor, J. et al. (Astra AB) Novel spiroazabicyclic heterocyclic compounds. WO 9903859.
11. Broad, L.M., Felthouse, C., Zwart, R. et al. PSAB-OFP, a selective alpha 7 nicotinic receptor agonist, is also a potent agonist of the 5-HT3 receptor. Eur J Pharmacol 2002, 452(2): 137-44.
12. Bodnar, A.L., Cortes-Burgos, L.A., Cook, K.K. et al. Discovery and structure-activity relationship of quinuclidine benzamides as agonists of alpha7 nicotinic acetylcholine receptors. J Med Chem 2005, 48(4): 905-8.
13. Hajos, M., Hurst, R.S., Hoffmann, W.E. et al. The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-azabicyclo[2.2.2] oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J Pharmacol Exp Ther 2005, 312(3): 1213-22.
14. 125/-α-bungaratoxin receptor subtypes. Mol Pharmacol 1995, 47: 164-71.
15. Biton, B., Bergis, O.E., Galli, R et al. SSR180711, a novel selective α7 nicotinic receptor partial agonist: (1) Binding and functional profile. Neuropsychopharmacology 2007, 32(1):1-16.
16. Tatsumi, R., Fujio, M., Takanashi, S. et al. (R)-3′-(3- Methylbenzo[b]thiophen-5-yl)spiro[1-azabicyclo[2,2,2]octane-3, 5′-oxazolidin]-2′-one, a novel and potent alpha7 nicotinic acetylcholine receptor partial agonist displays cognitive enhancing properties. J Med Chem 2006, 49(14): 4374-83.
17. Briggs, C.A., Anderson, D.J., Brioni, J.D. et al. Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol Biochem Behav 1997, 57(1-2): 231-41.
18. Astles, P.C., Baker, S.R., Boot, J.R. et al. Recent progress in the development of subtype selective nicotinic acetylcholine receptor ligands. Curr Drug Targets CNS Neurol Disord 2002, 1(4): 337-48.
19. Kern, V.R., Mahnir, V.M., Prokai, L. et al. Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): Their molecular properties, interactions with brain nicotinic receptors and brain penetration. Mol Pharmacol 2004, 65: 56-67.
20. Machu, T.K., Hamilton, M.E., Frye, T.F. et al. Benzylidene analogs of anabaseine display partial agonist and antagonist properties at the mouse 5-hydroxytryptamine3A receptor. J Pharmacol Exp Ther 2001, 299: 1112-9.
21. Phillips, E., Schmiesing, R. (AstraZeneca AB). Novel biaryl-carboxamides. WO 0160821.
22. Tatsumi, R., Seio, K., Fujio, M. et al. (+)-3-[2-(Benzo[b]thiophen-2- yl)-2-oxoethyl]-1-azabicyclo[2.2.2]octane as potent agonists for the alpha7 nicotinic acetylcholine receptor. Bioorg Med Chem Lett 2004, 14(14): 3781-4.
23. Tatsumi, R., Fujio, M., Satoh, H. et al. Discovery of the alpha7 nicotinic acetylcholine receptor agonists. (R)-3′-(5-Chlorothiophen-2-yl) spiro-1-azabicyclo[2.2.2]octane-3,5′-[1′,3′] oxazolidin-2′-one as a novel, potent, selective, and orally bioavailable ligand. J Med Chem 2005, 48(7): 2678-86.
24. Wishka, D.G., Walker, D.P., Yates, K.M. et al. Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia. Synthesis and structure-activity relationship. J Med Chem 2006, 49(14): 4425-36.
25. Jordan, K.J., Gatto, G.J., Hauser, T.A. et al. Assessment of a full α7 nicotinic acetylcholine receptor agonist, TC-5619, in animal models of schizophrenia. 35th Annu Meet Soc Neurosci (Nov 12-15, Washington, D.C.). 2005, Abst 952.10.
26. Feuerbach, D., Hurth, K., Ritchie, T.J. (Novartis AG; Novartis Pharma GmbH). Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonist. WO 2004022556.
27. Feuerbach, D., Roy, B.L., Troxler, T.J., Hurth, K. (Novartis AG; Novartis Pharma GmbH). 3-(Heteroaryl-oxy)-2-alkyl-1-azabicycloalkyl derivatives as alpha.7-nAChR ligands for the treatment of CNS diseases. WO 2006005608.
28. Kohlhaas, K.L., Rueter, L.E., Bitner, R.S. (Abbott Lab.). Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions. US 2006311686.
29. Empfield, J., Phillips, E., Throner, S. (AstraZeneca AB). 4-Substituted imidazoles. WO 2005049612.
30. Empfield, J., Phillips, E., Throner, S. (AstraZeneca AB). 5-Substituted imidazoles. WO 2005049611.
31. Ernst, G., Frietze, W., Jacobs, R., Phillips, E. (AstraZeneca AB). Nicotinic acetylcholine receptor ligands. WO 2005061510.
32. Benedetti, Y., Bohme, A., Genevois-Borella, A., Touyer, G., Zhang, J. (Aventis Pharma SA). Triazine derivatives, their preparation and therapeutic application thereof. WO 2006111662.
33. Herbert, B., Nguyen, T.M., Tehim, A., Hopper, A.T., Xie, W. (Memory Pharmaceuticals Corp.). Anabaseine derivatives useful in the treatment of neurodegenerative diseases. WO 2004019943.
34. Xie, W., Herbert, B., Schumacher, R., Nguyen, T.M., Ma, J., Gauss, C.M., Tehim, A. (Memory Pharmaceuticals Corp.), Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof. WO 2005092890.
35. Xie, W., Herbert, B., Nguyen, T.M., Gauss, C.M., Tehim, A. (Memory Pharmaceuticals Corp.). Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof. WO 2004029050.
36. Xie, W., Herbert, B., Schumacher, R.A., Ma, J., Nguyen, T.M., Gauss, C.M., Tehim, A. (Memory Pharmaceuticals Corp.). 1H-Indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof. WO 2005111038.
37. Luithle, J., Boess, F.-G., Erb, C. et al. (Bayer AG). Azabicyclic N-biarylamides with affinity for the alpha-7 nicotinic acetylcholine receptor. WO 03078431.
38. Plessner, T., Boess, F.-G., Erb, C. et al. (Bayer Healthcare AG). Benzothiophene urea, benzofurane urea, and indole urea, and use of the same as alpha-7 AChR agonists. WO 2004013136.
39. Zwart, R., De Filippi, G., Broad, L.M. et al. 5-Hydroxyindole potentiates human alpha 7 nicotinic receptor-mediated responses and enhances acetylcholine-induced glutamate release in cerebellar slices. Neuropharmacology 2002, 43(3): 374-84.
40. Krause, R.M., Buisson, B., Bertrand, S. et al. Ivermectin: A positive allosteric effector of the α7 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 1998, 53: 283-94.
41. Samochocki, M., Hoffle, A., Fehrenbacher, A. et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 2003, 305(3): 1024-36.
42. Broad, L.M., Zwart, R., Pearson, K.H. et al. Identification and pharmacological profile of a new class of selective nicotinic acetylcholine receptor potentiators. J Pharmacol Exp Ther 2006, 318(3): 1108-17.
43. Hurst, R.S., Hajos, M., Raggenbass, M. et al. A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: In vitro and in vivo characterization. J Neurosci 2005, 25(17): 4396-405.
44. Sher, E., Zwart, R., De Filippi, G. et al. Pharmacological and electrophysiological characterisation of a new class of selective alpha-7 nicotinic receptor potentiators. 35th Annu Meet Soc Neurosci (Nov 12-15, Washington, D.C.) 2005, Abst 951.10.
45. Maggi, L., Sher, E., Cherubini, E. Regulation of GABA release by nicotinic acetylcholine receptors in the neonatal rat hippocampus. J Physiol 2001, 536: 89-100.
46. Fujii, S., Sumikawa, K. Acute and chronic nicotine exposure reverse age-related declines in the induction of long-term potentiation in the rat hippocampus. Brain Res 2001, 894(2): 347-53.
47. Matsuyama, S., Matsumoto, A., Enomoto, T. et al. Activation of nicotinic acetylcholine receptors induces long-term potentiation in vivo in the intact mouse dentate gyrus. Eur J Neurosci 2000, 12(10): 3741-7.
48. Fernandes, C., Hoyle, E., Dempster, E. et al. Performance deficit of alpha7 nicotinic receptor knockout mice in a delayed matching-to-place task suggests a mild impairment of working/episodic-like memory. Genes Brain Behav 2006, 5(6): 433-40.
49. Hoyle, E., Genn, R.F., Fernandes, C. et al. Impaired performance of alpha7 nicotinic receptor knockout mice in the five-choice serial reaction time task. Psychopharmacology (Berl) 2006, 189(2): 211-23.
50. Young, J.W., Crawford, N., Kelly, J.S. et al. Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. Eur Neuropsychopharmacol 2007, 17(2): 145-55.
51. Young, J.W., Finlayson, K., Spratt, C. et al. Nicotine improves sustained attention in mice: Evidence for involvement of the alpha7 nicotinic acetylcholine receptor. Neuropsychopharmacology 2004, 29(5): 891-900.
52. Grottick, A.J., Higgins, G.A. Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task. Behav Brain Res 2000, 117(1-2): 197-208.
53. Nanri, M., Yamamoto, J., Miyake, H. et al. Protective effect of GTS-21, a novel nicotinic receptor agonist, on delayed neuronal death induced by ischemia in gerbils. Jpn J Pharmacol 1998, 76(1): 23-9.
54. Nanri, M., Miyake, H., Murakami, Y. et al. GTS-21, a nicotinic agonist, attenuates multiple infarctions and cognitive deficit caused by permanent occlusion of bilateral common carotid arteries in rats. Jpn J Pharmacol 1998, 78(4): 463-9.
55. Nanri, M., Kasahara, N., Yamamoto, J. et al. GTS-21, a nicotinic agonist, protects against neocortical neuronal cell loss induced by the nucleus basalis magnocellularis lesion in rats. Jpn J Pharmacol 1997, 74(3): 285-9.
56. Meyer, E.M., Tay, E.T., Papke, R.L. et al. 3-[2,4- Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat alpha7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner. Brain Res 1997, 768(1-2): 49-56.
57. Kem, W.R. The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: Studies with DMXBA (GTS-21). Behav Brain Res 2000, 113(1-2): 169-81.
58. Levin, E.D., Bettegowda, C., Blosser, J. et al. AR-R17779, an alpha7 nicotinic agonist, improves learning and memory in rats. Behav Pharmacol 1999, 10(6-7): 675-80.
59. Van Kampen, M., Selbach, K., Schneider, R. et al. AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors. Psychopharmacology (Berl) 2004, 172(4): 375-83.
60. Boess, F.G., De Vry, J., Erb, C. et al. The novel α7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2- (methoxy)phenyl]-1-benzofuran-2-carboxamide (ABBF) improves working and recognition memory in rodents. J Pharmacol Exp Ther 2007, Epub ahead of print.
61. O'Neill, M. J., Murray, T.K., Lakics, V. et al. The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration. Curr Drug Targets CNS Neurol Disord 2002, (4): 399-411.
62. Wang, H.Y., Lee, D.H., Davis, C.B. et al. Amyloid peptide Abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. J Neurochem 2000, 75(3): 1155-61.
63. Liu, Q., Kawai, H., Berg, D.K. Beta-amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons. Proc Natl Acad Sci USA 2001, 98(8): 4734-9.
64. Dineley, K.T., Bell, K.A., Bui, D. et al. Beta-amyloid peptide activates alpha 7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Biol Chem 2002, 277(28): 25056-61.
65. Dineley, K.T., Xia, X., Bui, D. et al. Accelerated plaque accumulation, associative learning deficits, and up-regulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J Biol Chem 2002, 277(25): 22768-80.
66. Kihara, T., Shimohama, S., Sawada, H. et al. Alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity. J Biol Chem 2001, 276(17): 13541-6.
67. Shaw, S., Bencherif, M., Marrero, M.B. Janus kinase 2, an early target of alpha 7 nicotinic acetylcholine receptor-mediated neuroprotection against Abeta-(1-42) amyloid. J Biol Chem 2002, 277(47): 44920-4.
68. Wang, H.Y., Li, W., Benedetti, N.J. et al. Alpha 7 nicotinic acetylcholine receptors mediate beta-amyloid peptide-induced tau protein phosphorylation. J Biol Chem 2003, 278(34): 31547-53.
69. Nordberg, A., Hellstrom-Lindahl, E., Lee, M. et al. Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). J Neurochem 2002, 81(3): 655-8.
70. Chen, L., Yamada, K., Nabeshima, T. et al. Alpha7 nicotinic acetylcholine receptor as a target to rescue deficit in hippocampal LTP induction in beta-amyloid infused rats. Neuropharmacology 2006, 50(2): 254-68.
71. Simosky J.K., Stevens, K.E., Kern, W.R. et al. Intragastric DMXB-A, an alpha7 nicotinic agonist, improves deficient sensory inhibition in DBA/2 mice. Biol Psychiatry 2001, 50(7): 493-500.
72. O'Neill, H.C., Rieger, K., Kern, W.R. et al. DMXB, an alpha7 nicotinic agonist, normalizes auditory gating in isolation-reared rats. Psychopharmacology (Berl) 2003, 169(3-4): 332-9.
73. Leonard, S., Adler, L.E., Benhammou, K. et al. Smoking and mental illness. Pharmacol Biochem Behav 2001, 70(4): 561-70.
74. Martin, L.F., Kern, W.R., Freedman, R. Alpha-7 nicotinic receptor agonists: Potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl) 2004, 174(1): 54-64.
75. Olincy, A., Harris, J.G., Johnson, L.L. et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2006, 63(6): 630-8.
76. Pichat, P., Bergis, O.E., Terranova, J.P. et al. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) Efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 2007, 32: 17-34.
77. Schreiber, R., Dalmus, M., De Vry, J. Effects of alpha 4/beta 2- and alpha 7-nicotine acetylcholine receptor agonists on pre-pulse inhibition of the acoustic startle response in rats and mice. Psychopharmacology (Berl) 2002, 159(3): 248-57.
78. Suemaru, K., Yasuda, K., Umeda, K. et al. Nicotine blocks apomorphine-induced disruption of prepulse inhibition of the acoustic startle in rats: Possible involvement of central nicotinic alpha7 receptors. Br J Pharmacol 2004, 142(5): 843-50.
79. Duncan, E., Madonick, S., Chakravorty, S. et al. Effects of smoking on acoustic startle and prepulse inhibition in humans. Psychopharmacology (Berl) 2001, 156(2-3): 266-72.
80. Ripoll, N., Bronnec, M., Bourin, M. Nicotinic receptors and schizophrenia. Curr Med Res Opin 2004, 20(7): 1057-74